The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study

Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased...

Descrición completa

Detalles Bibliográficos

Principais autores:	De-En Lu, Tsong-Yih Ou, Jyun-Wei Kang, Jie Ywi Ong, I-Ju Chen, Chih-Hsin Lee, Ming-Chia Lee
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2024-02-01
Series:	Journal of Microbiology, Immunology and Infection
Assuntos:	SARS-CoV-2 infection Secondary bloodstream infections Tocilizumab
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S1684118223002025
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!